Zymeworks Inc. (ZYME) Stock Price & How to Invest

Zymeworks is a biotechnology company incorporated in Delaware with roughly 231 employees, built around protein engineering: bispecific antibodies and antibody-drug conjugates aimed mainly at cancer. Its one approved medicine, zanidatamab, is sold as Ziihera by Jazz Pharmaceuticals in the United States and other licensed markets and by BeOne Medicines across its Asia-Pacific territories. Zymeworks does not market anything itself. Revenue arrives as tiered royalties (10% to 20% of Jazz's net sales, up to 19.5% of BeOne's) and as regulatory and commercial milestone payments, while the wholly owned pipeline of ADCs stays in early clinical testing.

That structure makes the reported numbers look strange next to the share price. Trailing twelve-month revenue of about $37.1 million against a ~$2.07 billion market value is roughly 56 times sales, and the line is lumpy because milestones dominate it: first-half 2026 revenue was ~$7.0 million versus ~$75.8 million a year earlier, almost entirely because 2025 carried large one-time payments that did not repeat. Strip those out and the recurring piece, royalties on Ziihera, was ~$3.4 million across the first half and grew quarter over quarter. On August 25, 2026 the FDA approved Ziihera combinations in first-line HER2-positive gastroesophageal adenocarcinoma, a far larger population than the 2024 biliary tract approval, triggering a ~$250 million milestone from Jazz. Losses continue in the meantime, at ~$45.0 million in the second quarter, funded from a ~$322.5 million cash and securities balance.

Zymeworks is not profitable and is not close to it on current product economics: the second quarter of 2026 produced a net loss of about $45.0 million on roughly $4.6 million of revenue, and operations run on a ~$322.5 million cash and securities balance plus lumpy partner payments rather than on product profits. Nearly all of the value sits in assets the company does not control commercially, because Jazz and BeOne decide how hard Ziihera is promoted and where, or in wholly owned candidates still in Phase 1 with no efficacy proven at scale. Pipeline failure is a live possibility rather than a theoretical one, as the ZW171 discontinuation showed. The Theravance purchase adds cash flow but also adds closing risk, a $350 million non-recourse note secured on the YUPELRI profit share, and the job of running a commercial respiratory business Zymeworks has never operated. One approved drug carries the entire royalty line, so a competitive setback in HER2 gastroesophageal cancer, where Enhertu and trastuzumab-based regimens are entrenched, would fall directly on the only recurring revenue the company has.

12 analysts publish price targets on ZYME, averaging $41.58 against a $29.01 price as of August 2026, or +43.3%. The published targets run from $31.00 to $60.00, a moderate spread, and the ratings split 12 buy, 0 hold, 0 sell. Over the last six months there have been 11 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full ZYME forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Zymeworks Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Ziihera moves into first-line gastric cancer. The August 2026 approval covers Ziihera with and without tislelizumab alongside chemotherapy in first-line HER2-positive gastroesophageal adenocarcinoma, based on the Phase 3 HERIZON-GEA-01 trial. The most optimistic published target, $60.00, assumes this works close to its best case.

The case against. Zymeworks is not profitable and is not close to it on current product economics: the second quarter of 2026 produced a net loss of about $45.0 million on roughly $4.6 million of revenue, and operations run on a ~$322.5 million cash and securities balance plus lumpy partner payments rather than on product profits. The most pessimistic target, $31.00, is roughly what ZYME is worth if this bites instead.

Read the full bull and bear case on ZYME, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Zymeworks Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$37.1M
• Royalty revenue (Q2 2026): ~$1.8M
• Net loss (Q2 2026): ~$45.0M
• Cash and marketable securities (Jun 30, 2026): ~$322.5M
• Market cap: ~$2.07B
• Price to sales (TTM): ~56x

The sales multiple is close to meaningless here because the revenue line mixes a small growing royalty with large one-off milestones, so it swings by an order of magnitude between years. A more useful frame is the two pieces separately: royalties of ~$1.8 million in the second quarter that track Jazz's Ziihera sales, and a milestone stack of up to ~$1.3 billion that pays only on events. Second-quarter research and development spending fell about 20% year over year to ~$27.4 million while general and administrative costs rose to ~$19.3 million, and management stopped issuing cash runway guidance in August 2026, citing the shift toward a revenue-generating model.

Other names that sit close to ZYME: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get ZYME exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so ZYME sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where ZYME fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Zymeworks is a royalty and milestone claim on a partner's commercial execution, priced today on what Ziihera and a pending acquisition might earn rather than on what the business currently collects.

Whether ZYME is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is ZYME a buy or a sell?, and where the stock could go from here in the ZYME stock forecast.

For income investors, whether ZYME pays a dividend and how the payout looks is covered in does ZYME pay a dividend? And to weigh ZYME against a peer, read the full side-by-side comparisons: ZYME vs AZN and ZYME vs JAZZ.